Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II). (Formulae (I, (II))
-
Page/Page column 36; 42
(2019/02/17)
cGAS ANTAGONIST COMPOUNDS
Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
-
Paragraph 0219; 0297; 0314
(2017/11/06)
SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF
Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
-
Page/Page column 387
(2014/09/29)
SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF
Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
-
Paragraph 0311; 0312
(2014/09/30)
(2,5)Pyrimidinophanes: Synthesis and Molecular Structure
The title compounds 1 and 2 are synthesized by photolytic sulfur extrusion from 2,11-dithia(2,5)pyrimidinophane 17.The molecular structures of 1 and 2 are determined by X-ray structure analysis and are discussed with regard to the steric strain in these molecules.Thermolysis of - or -trimethylammonium hydroxide (10 or 11) does not generate 1 and 2. α-Chlorination of 2,5-dimethylpyrimidine (3) with N-chlorosuccinimide provides the required precursors 4 - 6.
Eiermann, Uwe,Krieger, Claus,Neugebauer, Franz A.
p. 1885 - 1889
(2007/10/02)
More Articles about upstream products of 126504-86-7